

The Etiology, Diagnosis, and Treatment of Chronic Coronary Syndrome

Problem Statement

Managing chronic coronary syndrome (CCS) involves a wide variety of procedures, which can be considered quite intricate as well as heterogeneous. Although these guidelines were developed in order to enhance the quality of CCS management, all of the suggestions made are not the same (Jing et al., 2023). In the year 2019, the European Society of Cardiology (ESC) had a huge transformation in diagnosis and treatment that defines chronic coronary syndrome (CCS) as coronary artery disease (CAD). The alteration in terminology from “SCAD” or ‘stable coronary artery disease’ to “CCS” could be due to the resting of CAD, this in turn entails the subsequent emergence of both, the condition known as ACS or acute coronary syndrome and CCS. These guidelines define coronary artery disease as a chronic process (Jurisch & Laufs, 2021), however, atherosclerotic lesions in the vascular system are also suggested as being active (Luescher, 2019), they involve several regions of the coronary circulation, and in addition, the disease changing or evolving should be considered. Another clinical sign prevailing in coronary thrombosis, but also the phases of progression of coronary heart disease without symptoms, myocardial ischemia, vasospasm, and microcirculation lesions also indicate. This awareness leads to a more comprehensive understanding that coronary heart disease is an evolving process which has deposition of atheroma and changes in the functions of coronary circulation.

It shows that coronary heart disease is not passive, but on the contrary, goes through sudden relatively settled intervals as well as periods of plaque rupture, plaque erosion and calcified nodules. Accordingly, the new Chinese guidelines from 2018 consider stable coronary heart disease as the culmination of the course after ischemic cardiomyopathy, chronic stable labor angina, and ACS, which have the same pathophysiology and etiology. Guo and Huang (2019) explain that these disorders are called CCS patients. Thus, even the guidelines developed prior to 2019 qualify for this systematic review of findings regarding stable coronary artery disease, chronic coronary artery disease, chronic myocardial ischemia syndrome, stable angina and exertion angina. A major source of morbidity and death (Jakob et al., 2021), CCS is a high priority challenge for global concerns on health and safety because of its unusually high fatality rate and is an emerging epidemiological problem worldwide (Cheng et al., 2021). Therefore, the improvement of the therapy of patients with CCS is the main challenge.

In addition to marking a change in nomenclature, the introduction of the notion of CCS signifies a better understanding of the pathophysiology of CAD by clinical researchers. By going beyond just concentrating on inducible ischemia, this paradigm change highlights the importance of atherosclerotic burden—a subtlety that has been inadequately represented in current CPGs. There are clear differences in the quality and suggestions made by the published CCS-specific guidelines, highlighting the necessity of multidisciplinary cooperation in creating thorough and empirically supported CPGs. These recommendations are essential for promoting the best possible treatment plans and enhancing the health of those who are struggling with CCS (Jing et al., 2023). Although remarkable progress has been achieved in the diagnosis and treatment of acute coronary syndromes, cardiovascular disease remains the leading cause of death worldwide, with ischemic heart disease being responsible for about fifty percent of these deaths. Shortened time-to-rule-out for patients with non-ST-segment elevated myocardial infarction (NSTEMI) via the growing availability of high-sensitivity troponin test has been made possible by the rapid rule-out algorithms (Bergmark et al, 2022). One common sign of coronary artery disease (CAD) is chronic coronary syndromes (CCS), also known as previously stable angina (SA) (Hemingway et al., 2006). It results from increased life expectancy, an increase in the prevalence of risk factors for CAD, and better outcomes for ACS patients (Pikala et al., 2017). The European Society of Cardiology (ESC) has revised the recommendations for CCS care three times due to major advancements in the diagnosis and treatment of CAD (Fox et al., 2006; Montalescot et al., 2013; Knuuti et al., 2020). Modifications to the guidelines for treating individuals with CCS necessitate ongoing clinical practice monitoring of treatment outcomes. Nevertheless, there aren't many research on the short- and long-term results for this patient population (Trzeciak 2018). In terms of clinical features, management, and therapy, carefully chosen individuals who are frequently not representative of populations in everyday practice are frequently recruited for randomized trials and international registries (Sorbetts et al., 2017). A major worldwide health burden, chronic coronary syndrome is defined by ongoing myocardial ischemia brought on by either obstructive or non-obstructive coronary artery disease. Effective diagnosis and individualized therapy are made more difficult by the incomplete understanding of the etiological complexity of CCS, despite advances in cardiovascular research. Although they are helpful in controlling symptoms and lowering acute cardiovascular events, traditional therapy methods sometimes overlook the complex nature of CCS, which includes new elements

such inflammation, microvascular dysfunction, and hereditary predispositions. Furthermore, it is difficult for current diagnostic methods to correctly identify a variety of patient categories, especially those with atypical presentations or non-obstructive coronary artery disease. This disparity emphasizes the need for creative fixes to enhance therapy results and increase diagnostic accuracy. Additionally, the emergence of cutting-edge technology like artificial intelligence, sophisticated imaging techniques, and cutting-edge treatments like gene editing and regenerative medicine offers a once-in-a-lifetime chance to revolutionize the management of CCS. However, due to a lack of study on their application, safety, and efficacy, the incorporation of these developments into clinical practice is still in its infancy. In order to overcome these obstacles, a thorough investigation of the underlying etiological processes of CCS, new diagnostic developments, and potential treatment approaches is required. Such a strategy is essential for improving patient care, lowering the burden of disease worldwide, and developing more potent medical therapies.

Research Questions

- What are the emerging etiological factors contributing to the pathogenesis of Chronic Coronary Syndrome, and how do they differ from traditional risk factors?
- How can novel diagnostic technologies and emerging therapeutic approaches improve the management and outcomes of patients with Chronic Coronary Syndrome?

Literature review

The concept "etiology" on the other hand is the fundamental reasons and contributing elements to the development and advancement of CCS. Atherosclerosis is a series of lipid buildup, inflammatory cells, and fibrous elements that are creeping Progressive disorder that is marked by the accumulation of lipids, inflammatory cells, and fibrous components inside the artery wall. The very beginning of the process is the damage of the blood vessels by the endothelium which is the basis of the rest (Alifu et al, 2023). The endothelium plays a significant role in the maintenance of an anti-inflammatory environment and the control of vascular tone and thrombosis. In these cases, the actions of cytokines and chemokines, by the recruitment and retention of monocytes, activate the endothelium and immune cells to the vascular wall which is characterized by the decrease of nitric oxide bioavailability, the augmentation of oxidative

stress, and the increase of adhesion molecules (Berge et al, 2022). Common risk factors are a major theme in the creation of CCS, and most work together to compound the problem. Dyslipidemia, specifically, exaggerated concentrations of LDL-C and decreased levels of HDL-C have a significant impact on the development and progression of atherosclerotic plaques. In the arterial wall, macrophages actively absorb oxidized LDL particles, which are their major food, by way of the scavenger receptors detachment upon the modification of their particle structure especially under oxidative stress circumstances. Feared inflammation is the giant of factors causing CCS as it is a major way by which the process of plaque, instability and eventual debilitating disease is sustained. Vascular injury is exacerbated by a vicious cycle of immune activation mediated by cytokines, chemokines, and other inflammatory mediators (Zhang et al, 2023). Apart from dyslipidemia, hypertension is another important risk factor associated with the development of CCS. High-pressure conditions provoke damage of the endothelium, which is a result of mechanical stress to the artery walls and enhancement in the ease of penetration of athero-prone particles. Moreover, hypertension induces hypertrophy of vascular smooth muscle cells and remodeling of the extracellular matrix. This, in turn, can make plaque more or less stable. Diabetes mellitus betters the situation by signaling the body to produce insulin resistance and prolonged hyperglycemia. Also, it causes the exacerbation of oxidative stress, inflammation, and endothelial dysfunction, and this could exacerbate current problems. Diabetic dyslipidemia, which is characterized by small and dense LDL particles and high triglycerides, is an added layer of complication. It exacerbates the risk of the development and progression of atherosclerotic plaque (Zhao et al, 2023). The etiology of CCS is also significantly influenced by genetic predisposition; recent studies have shown that some genetic factors may be the cause of some people developing the disease.

Due to its ability to reveal otherwise hidden coronary plaques that may satisfy the criteria for being non-obstructive, ICCA is now recommended as one of the most preferable diagnostic options for those who have been diagnosed with CCS. As Ueng et al. (2023) Have stated, this method improves risk assessment processes making it non-invasive. Most of the clinical indications under the Patient Population for CCS are as follows: (i) Patients who have a history of stable angina and/or dyspnea but whose coronary artery disease (CAD) has yet to be diagnosed (ii) Patients with CAD who were asymptomatic at the beginning but whose heart failure or left ventricle ischemia developed later (iii) Patients who have undergone recent

coronary stenting or placement of a bypass graft and are otherwise stable (iv) Patients who were previously diagnosed with CAD but were stent free for the past year or so and (v) Patients suffering from angina who also have suspected spasm and or inflammation or microvascular disease. (vi) Those who are asymptomatic but CAD is identified through screening procedures (Knuuti et al. 2020). The diagnosis of obstructive CAD, ruling out differential diagnoses as well as assessing the extent of the disease process itself, often requires objective methods, assessments, imagine or tests and so forth due to the fact that the symptoms of the disease itself appear to be many in number and are at times rather odd in presentation (Antti & Juhani, 2020). A physical examination is essential in the case of a patient who is suspected to have coronary artery disease (CAD) but also has anemia, hypertension, valvular heart disease, hypertrophic cardiomyopathy, or arrhythmias. Other historical information, such as body mass index (BMI) or other concomitant disorders including diabetes, thyroid disease, or renal disease, is also recommended. Isolated non-coronary vascular disease may present significant and ominous findings on the auscultation of the carotid and femoral arteries, on the palpation of peripheral pulses, and the ankle-brachial index (ABI) test. It should also be taken along with other clinical information including the presence or absence of cough or stinging pain in the chest so that the CAD possibility can be minimized. The presence of sublingual nitroglycerin and the ability to elicit the symptoms by the application of manual thumb pressure in the relevant region may also be evaluated so as to classify the symptoms (Bösner et al., 2010)

In general, the patient's health status, his comorbidities and status as a functional patient should be considered before any of the tests are directed. Further tests may be performed but for clinically necessary minimum only, where revascularisation is unlikely to be a preferred option. Once again, a treatment regimen appropriate for the patient must be put in place and even then an antianginal drug trial may even be commenced though gout is not fully defined.

In case the diagnosis has to be further substantiated, one could keep in mind imfunctional imaging for ischaemia. However, this may not always be the case, and if one decides not to pursue surgery, it is advisable to perform other diagnostic examinations as well, such as pulmonary and musculoskeletal examinations in case of apparent angina at least. However, Piepoli and others (2016) argue that these people should also be targeted with guidelines-based risk-factor modification relying on commonly used risk charts such as SCORE (Systematic Coronary Risk Evaluation).

Research Methods

Using a systematic review technique, this study will examine the body of research on the causes, symptoms, and management of chronic coronary syndrome (CCS). Peer-reviewed publications listed on Google Scholar will serve as the main source of data, guaranteeing access to scholarly research that is reputable, varied, and of high quality. To obtain a thorough selection of papers, pertinent keywords like "Chronic Coronary Syndrome," "etiology," "diagnosis," "emerging therapies," and "novel treatments" will be used.

Recent publications (within the previous ten years) will be given priority in the inclusion criteria in order to capture the newest developments and developing trends. To keep the focus on new discoveries, papers that explain traditional approaches will not be accepted. In order to provide a comprehensive picture of the state of CCS research today, the collected data will be combined to find trends, gaps, and potential future directions. By combining knowledge from many research into a logical framework for comprehending and treating CCS, this review seeks to make a contribution.

References

- Alifu, J., Xiang, L., Zhang, W., Qi, P., Chen, H., Liu, L., ... & Che, W. (2023). Association between the atherogenic index of plasma and adverse long-term prognosis in patients diagnosed with chronic coronary syndrome. *Cardiovascular diabetology*, 22(1), 255.
- Antti, S., & Juhani, K. (2020). ESC 2019 guidelines for the diagnosis and management of chronic coronary syndromes. *Herz*, 45(5), 409-420.
- Berge, C. A., Eskerud, I., Almeland, E. B., Larsen, T. H., Pedersen, E. R., Rotevatn, S., & Lønnebakken, M. T. (2022). Relationship between hypertension and non-obstructive coronary artery disease in chronic coronary syndrome (the NORIC registry). *Plos one*, 17(1), e0262290.
- Bösner, S., Haasenritter, J., Becker, A., Karatolios, K., Vaucher, P., Gencer, B., ... & Donner-Banzhoff, N. (2010). Ruling out coronary artery disease in primary care: development and validation of a simple prediction rule. *Cmaj*, 182(12), 1295-1300.
- Cheng, K., Alhumood, K., El Shaer, F., & De Silva, R. (2021). The role of nicorandil in the management of chronic coronary syndromes in the gulf region. *Advances in Therapy*, 38(2), 925-948.
- Fox, K., Garcia, M. A., Ardissino, D., et al. (2006). Task force on the management of stable angina pectoris of the European Society of Cardiology, ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. *European Heart Journal*, 27(11), 1341–1381. <https://doi.org/10.1093/eurheartj/ehl001>. Indexed in PubMed: 16735367.
- Guo, H.-Z. & Huang, R.-C. (2019). Interpretation of 2019 ESC guidelines for chronic coronary syndrome, *Chinese Circulation Journal*, 34(S1), 18–23.
- Hemingway, H., McCallum, A., Shipley, M., et al. (2006). Incidence and prognostic implications of stable angina pectoris among women and men. *JAMA*, 295(12), 1404–1411. <https://doi.org/10.1001/jama.295.12.1404>. Indexed in PubMed: 16551712.
- Jakob, P., Holy, E. W., Siegrist, P., Michel, J., Manka, R., Kasel, M., ... & Stähli, B. E. (2021). Perkutane koronare Revaskularisation beim chronischen Koronarsyndrom: wann sinnvoll, wann nicht?. *Praxis*.
- Jing, T., Wang, Y., Li, Y., Cui, L., Liu, X., Liu, D., ... & Wang, L. (2023). Diagnosis, treatment, and management for chronic coronary syndrome: A systematic review of clinical practice guidelines and consensus

- statements. *International Journal of Clinical Practice*, 2023(1), 9504108.
- Jurisch, D., & Laufs, U. (2021). Chronic coronary syndrome: New classification of stable coronary artery disease. *Der Internist*, 62, 47-57.
- Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., ... & Bax, J. J. (2020). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). *European heart journal*, 41(3), 407-477.
- Luescher, T. F. (2019). Chronic coronary syndromes: genetics, shear stress, and biomarkers. *European Heart Journal*, 40(41), 3367-3371.
- Montalescot, G., Sechtem, U., Achenbach, S., et al. (2013). Task Force Members, ESC committee for practice guidelines, document reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *European Heart Journal*, 34(38), 2949–3003. <https://doi.org/10.1093/eurheartj/ehz296>. Indexed in PubMed: 23996286.
- Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., ... & Binno, S. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Polish Heart Journal (Kardiologia Polska)*, 74(9), 821-936.
- Pikala, M., Maniecka-Bryła, I., Pikala, M., et al. (2017). Fifteen-year mortality trends due to cardiovascular diseases in Poland using standard expected years of life lost, 2000–2014. *Kardiologia Polska*, 75(10), 1033–1040. <https://doi.org/10.5603/KP.a2017.0124>. Indexed in PubMed: 28715075.
- Sorbets, E., Greenlaw, N., Ferrari, R., et al. (2017). CLARIFY Investigators. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. *Clinical Cardiology*, 40(10), 797–806. <https://doi.org/10.1002/clc.22730>. Indexed in PubMed: 28561986.
- Trzeciak, P., Desperak, P., Ciślak, A., et al. (2018). Clinical characteristics, and in-hospital and long-term outcomes of stable angina treatment in patients below and over 40 years of age (from the PRESAGE registry). *Kardiologia Polska*, 76(1), 186–194. <https://doi.org/10.5603/KP.a2017.0200>. Indexed in PubMed: 29168551.
- Ueng, K. C., Chiang, C. E., Chao, T. H., Wu, Y. W., Lee, W. L., Li, Y. H., ... & Hou, C. J. Y. (2023). 2023 Guidelines of the Taiwan Society of Cardiology on the diagnosis and management of chronic coronary syndrome. *Acta Cardiologica Sinica*, 39(1), 4
- Zhang, H. W., Guo, Y. L., Wu, N. Q., Zhu, C. G., Dong, Q., Sun, J., ... & Li, J. J. (2023). Low-density lipoprotein triglyceride predicts outcomes in patients with chronic coronary syndrome following percutaneous coronary intervention according to inflammatory status. *Clinica Chimica Acta*, 551, 117631.
- Zhao, J., Zhang, H., Liu, C., Zhang, Y., Xie, C., Wang, M., ... & Zhou, J. (2023). Identification of vulnerable non-culprit lesions by coronary computed tomography angiography in patients with chronic coronary syndrome and diabetes mellitus. *Frontiers in Cardiovascular Medicine*, 10, 1143119.